Natera, Inc. $NTRA Shares Acquired by Envestnet Asset Management Inc.

Envestnet Asset Management Inc. lifted its stake in shares of Natera, Inc. (NASDAQ:NTRA) by 5.9% in the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 172,022 shares of the medical research company’s stock after buying an additional 9,651 shares during the quarter. Envestnet Asset Management Inc. owned approximately 0.13% of Natera worth $29,061,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also recently added to or reduced their stakes in the business. Bank of Jackson Hole Trust acquired a new stake in shares of Natera during the first quarter worth $29,000. TCTC Holdings LLC boosted its holdings in shares of Natera by 114.8% in the 1st quarter. TCTC Holdings LLC now owns 232 shares of the medical research company’s stock valued at $33,000 after buying an additional 124 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in shares of Natera by 83.5% in the 1st quarter. Northwestern Mutual Wealth Management Co. now owns 233 shares of the medical research company’s stock valued at $33,000 after buying an additional 106 shares during the period. Hilltop National Bank acquired a new position in shares of Natera in the 2nd quarter valued at about $33,000. Finally, Oliver Lagore Vanvalin Investment Group acquired a new position in shares of Natera in the 2nd quarter valued at about $36,000. Institutional investors and hedge funds own 99.90% of the company’s stock.

Natera Stock Up 3.0%

Shares of NASDAQ NTRA opened at $198.93 on Monday. Natera, Inc. has a fifty-two week low of $120.67 and a fifty-two week high of $199.21. The firm’s 50-day simple moving average is $174.44 and its 200 day simple moving average is $162.08. The stock has a market cap of $27.30 billion, a P/E ratio of -104.15 and a beta of 1.74.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Thursday, August 7th. The medical research company reported ($0.74) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.60) by ($0.14). Natera had a negative net margin of 12.89% and a negative return on equity of 22.22%. The company had revenue of $546.60 million for the quarter, compared to the consensus estimate of $476.84 million. During the same quarter in the prior year, the firm earned ($0.30) earnings per share. Natera’s revenue for the quarter was up 32.2% compared to the same quarter last year. Natera has set its FY 2025 guidance at EPS. On average, sell-side analysts anticipate that Natera, Inc. will post -1.49 earnings per share for the current fiscal year.

Insider Activity at Natera

In related news, insider Solomon Moshkevich sold 1,198 shares of Natera stock in a transaction dated Tuesday, October 28th. The shares were sold at an average price of $191.46, for a total transaction of $229,369.08. Following the sale, the insider directly owned 115,061 shares in the company, valued at $22,029,579.06. The trade was a 1.03% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Michael Burkes Brophy sold 1,867 shares of Natera stock in a transaction dated Wednesday, October 29th. The shares were sold at an average price of $190.64, for a total transaction of $355,924.88. Following the sale, the chief financial officer owned 64,126 shares in the company, valued at approximately $12,224,980.64. This represents a 2.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold 61,064 shares of company stock valued at $10,477,848 in the last ninety days. Company insiders own 5.63% of the company’s stock.

Analyst Ratings Changes

Several research analysts have recently commented on NTRA shares. BTIG Research lifted their price target on shares of Natera from $200.00 to $210.00 and gave the company a “buy” rating in a report on Thursday, October 23rd. Stephens reaffirmed an “overweight” rating and issued a $183.00 price target on shares of Natera in a report on Friday, August 15th. Morgan Stanley reiterated an “overweight” rating and issued a $195.00 target price on shares of Natera in a research note on Sunday, August 10th. Royal Bank Of Canada set a $268.00 target price on Natera and gave the company an “outperform” rating in a research note on Tuesday, September 2nd. Finally, BNP Paribas upgraded Natera to a “hold” rating and set a $172.00 target price on the stock in a research note on Monday, October 27th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating, three have given a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, Natera has an average rating of “Moderate Buy” and a consensus price target of $194.89.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.